Citadel Advisors
PBM icon

Citadel Advisors’s Psyence Biomedical PBM Stock Holding History

Citadel Advisors’s Portfolio PBM Stock Details PBM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,512
Closed -$45.2K – 15466
2025
Q1 		$45.2K Buy
1,512
+1,281
+555% +$81.5K ﹤0.01% 12408
2024
Q4 		$24.2K Buy
231
+186
+413% +$44.3K ﹤0.01% 13046
2024
Q3 		$16.9K Buy
+45
New +$60.9K ﹤0.01% 12908

Other funds holding PBM

PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SFFS
Stonehage Fleming Financial Services St. Helier, Jersey $2.75B AUM 13.81% 1-Year Est. Return

Citadel Advisors's PBM Position: Q2 2025 in Review

Citadel Advisors sold out of Psyence Biomedical (PBM) in Q2 2025, closing a stake of 1,512 shares — an estimated $45.2K sold.

Citadel Advisors first reported a position in PBM in Q3 2024 and held it in 3 quarters. The position peaked at $45.2K in Q1 2025. 6 funds tracked by Wall St. Rank hold PBM as of Q2 2025.

  • Citadel Advisors reported no remaining Psyence Biomedical position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 1,512 Psyence Biomedical shares in Q2 2025, an estimated $45.2K.
  • Citadel Advisors first reported a position in Psyence Biomedical in Q3 2024 and held it in 3 quarters.
  • Citadel Advisors's Psyence Biomedical position peaked at $45.2K in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Psyence Biomedical as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.